Medical Care

Global Long-Acting Monoclonal Antibodies Market Research Report 2025

The global market for Long-Acting Monoclonal Antibodies was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
North American market for Long-Acting Monoclonal Antibodies is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Long-Acting Monoclonal Antibodies is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global market for Long-Acting Monoclonal Antibodies in Cancer is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Long-Acting Monoclonal Antibodies include Eli Lilly, Abbott Laboratories, AstraZeneca, Amgen, Bayer AG, Johnson & Johnson, Pfizer, GlaxoSmithKline, Merck, Novartis, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Long-Acting Monoclonal Antibodies, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Long-Acting Monoclonal Antibodies.
The Long-Acting Monoclonal Antibodies market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Long-Acting Monoclonal Antibodies market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Long-Acting Monoclonal Antibodies companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Eli Lilly
Abbott Laboratories
AstraZeneca
Amgen
Bayer AG
Johnson & Johnson
Pfizer
GlaxoSmithKline
Merck
Novartis
Segment by Type
Murine Source
Chimeric Source
Human Source
Segment by Application
Cancer
Autoimmune Diseases
Inflammatory Diseases
Infectious Diseases
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Long-Acting Monoclonal Antibodies company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Long-Acting Monoclonal Antibodies Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Murine Source
1.2.3 Chimeric Source
1.2.4 Human Source
1.3 Market by Application
1.3.1 Global Long-Acting Monoclonal Antibodies Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Cancer
1.3.3 Autoimmune Diseases
1.3.4 Inflammatory Diseases
1.3.5 Infectious Diseases
1.3.6 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Long-Acting Monoclonal Antibodies Market Perspective (2020-2031)
2.2 Global Long-Acting Monoclonal Antibodies Growth Trends by Region
2.2.1 Global Long-Acting Monoclonal Antibodies Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Long-Acting Monoclonal Antibodies Historic Market Size by Region (2020-2025)
2.2.3 Long-Acting Monoclonal Antibodies Forecasted Market Size by Region (2026-2031)
2.3 Long-Acting Monoclonal Antibodies Market Dynamics
2.3.1 Long-Acting Monoclonal Antibodies Industry Trends
2.3.2 Long-Acting Monoclonal Antibodies Market Drivers
2.3.3 Long-Acting Monoclonal Antibodies Market Challenges
2.3.4 Long-Acting Monoclonal Antibodies Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Long-Acting Monoclonal Antibodies Players by Revenue
3.1.1 Global Top Long-Acting Monoclonal Antibodies Players by Revenue (2020-2025)
3.1.2 Global Long-Acting Monoclonal Antibodies Revenue Market Share by Players (2020-2025)
3.2 Global Long-Acting Monoclonal Antibodies Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Long-Acting Monoclonal Antibodies Revenue
3.4 Global Long-Acting Monoclonal Antibodies Market Concentration Ratio
3.4.1 Global Long-Acting Monoclonal Antibodies Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Long-Acting Monoclonal Antibodies Revenue in 2024
3.5 Global Key Players of Long-Acting Monoclonal Antibodies Head office and Area Served
3.6 Global Key Players of Long-Acting Monoclonal Antibodies, Product and Application
3.7 Global Key Players of Long-Acting Monoclonal Antibodies, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Long-Acting Monoclonal Antibodies Breakdown Data by Type
4.1 Global Long-Acting Monoclonal Antibodies Historic Market Size by Type (2020-2025)
4.2 Global Long-Acting Monoclonal Antibodies Forecasted Market Size by Type (2026-2031)
5 Long-Acting Monoclonal Antibodies Breakdown Data by Application
5.1 Global Long-Acting Monoclonal Antibodies Historic Market Size by Application (2020-2025)
5.2 Global Long-Acting Monoclonal Antibodies Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Long-Acting Monoclonal Antibodies Market Size (2020-2031)
6.2 North America Long-Acting Monoclonal Antibodies Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Long-Acting Monoclonal Antibodies Market Size by Country (2020-2025)
6.4 North America Long-Acting Monoclonal Antibodies Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Long-Acting Monoclonal Antibodies Market Size (2020-2031)
7.2 Europe Long-Acting Monoclonal Antibodies Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Long-Acting Monoclonal Antibodies Market Size by Country (2020-2025)
7.4 Europe Long-Acting Monoclonal Antibodies Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Long-Acting Monoclonal Antibodies Market Size (2020-2031)
8.2 Asia-Pacific Long-Acting Monoclonal Antibodies Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Long-Acting Monoclonal Antibodies Market Size by Region (2020-2025)
8.4 Asia-Pacific Long-Acting Monoclonal Antibodies Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Long-Acting Monoclonal Antibodies Market Size (2020-2031)
9.2 Latin America Long-Acting Monoclonal Antibodies Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Long-Acting Monoclonal Antibodies Market Size by Country (2020-2025)
9.4 Latin America Long-Acting Monoclonal Antibodies Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Long-Acting Monoclonal Antibodies Market Size (2020-2031)
10.2 Middle East & Africa Long-Acting Monoclonal Antibodies Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Long-Acting Monoclonal Antibodies Market Size by Country (2020-2025)
10.4 Middle East & Africa Long-Acting Monoclonal Antibodies Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Eli Lilly
11.1.1 Eli Lilly Company Details
11.1.2 Eli Lilly Business Overview
11.1.3 Eli Lilly Long-Acting Monoclonal Antibodies Introduction
11.1.4 Eli Lilly Revenue in Long-Acting Monoclonal Antibodies Business (2020-2025)
11.1.5 Eli Lilly Recent Development
11.2 Abbott Laboratories
11.2.1 Abbott Laboratories Company Details
11.2.2 Abbott Laboratories Business Overview
11.2.3 Abbott Laboratories Long-Acting Monoclonal Antibodies Introduction
11.2.4 Abbott Laboratories Revenue in Long-Acting Monoclonal Antibodies Business (2020-2025)
11.2.5 Abbott Laboratories Recent Development
11.3 AstraZeneca
11.3.1 AstraZeneca Company Details
11.3.2 AstraZeneca Business Overview
11.3.3 AstraZeneca Long-Acting Monoclonal Antibodies Introduction
11.3.4 AstraZeneca Revenue in Long-Acting Monoclonal Antibodies Business (2020-2025)
11.3.5 AstraZeneca Recent Development
11.4 Amgen
11.4.1 Amgen Company Details
11.4.2 Amgen Business Overview
11.4.3 Amgen Long-Acting Monoclonal Antibodies Introduction
11.4.4 Amgen Revenue in Long-Acting Monoclonal Antibodies Business (2020-2025)
11.4.5 Amgen Recent Development
11.5 Bayer AG
11.5.1 Bayer AG Company Details
11.5.2 Bayer AG Business Overview
11.5.3 Bayer AG Long-Acting Monoclonal Antibodies Introduction
11.5.4 Bayer AG Revenue in Long-Acting Monoclonal Antibodies Business (2020-2025)
11.5.5 Bayer AG Recent Development
11.6 Johnson & Johnson
11.6.1 Johnson & Johnson Company Details
11.6.2 Johnson & Johnson Business Overview
11.6.3 Johnson & Johnson Long-Acting Monoclonal Antibodies Introduction
11.6.4 Johnson & Johnson Revenue in Long-Acting Monoclonal Antibodies Business (2020-2025)
11.6.5 Johnson & Johnson Recent Development
11.7 Pfizer
11.7.1 Pfizer Company Details
11.7.2 Pfizer Business Overview
11.7.3 Pfizer Long-Acting Monoclonal Antibodies Introduction
11.7.4 Pfizer Revenue in Long-Acting Monoclonal Antibodies Business (2020-2025)
11.7.5 Pfizer Recent Development
11.8 GlaxoSmithKline
11.8.1 GlaxoSmithKline Company Details
11.8.2 GlaxoSmithKline Business Overview
11.8.3 GlaxoSmithKline Long-Acting Monoclonal Antibodies Introduction
11.8.4 GlaxoSmithKline Revenue in Long-Acting Monoclonal Antibodies Business (2020-2025)
11.8.5 GlaxoSmithKline Recent Development
11.9 Merck
11.9.1 Merck Company Details
11.9.2 Merck Business Overview
11.9.3 Merck Long-Acting Monoclonal Antibodies Introduction
11.9.4 Merck Revenue in Long-Acting Monoclonal Antibodies Business (2020-2025)
11.9.5 Merck Recent Development
11.10 Novartis
11.10.1 Novartis Company Details
11.10.2 Novartis Business Overview
11.10.3 Novartis Long-Acting Monoclonal Antibodies Introduction
11.10.4 Novartis Revenue in Long-Acting Monoclonal Antibodies Business (2020-2025)
11.10.5 Novartis Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Long-Acting Monoclonal Antibodies Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Murine Source
Table 3. Key Players of Chimeric Source
Table 4. Key Players of Human Source
Table 5. Global Long-Acting Monoclonal Antibodies Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 6. Global Long-Acting Monoclonal Antibodies Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 7. Global Long-Acting Monoclonal Antibodies Market Size by Region (2020-2025) & (US$ Million)
Table 8. Global Long-Acting Monoclonal Antibodies Market Share by Region (2020-2025)
Table 9. Global Long-Acting Monoclonal Antibodies Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 10. Global Long-Acting Monoclonal Antibodies Market Share by Region (2026-2031)
Table 11. Long-Acting Monoclonal Antibodies Market Trends
Table 12. Long-Acting Monoclonal Antibodies Market Drivers
Table 13. Long-Acting Monoclonal Antibodies Market Challenges
Table 14. Long-Acting Monoclonal Antibodies Market Restraints
Table 15. Global Long-Acting Monoclonal Antibodies Revenue by Players (2020-2025) & (US$ Million)
Table 16. Global Long-Acting Monoclonal Antibodies Market Share by Players (2020-2025)
Table 17. Global Top Long-Acting Monoclonal Antibodies Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Long-Acting Monoclonal Antibodies as of 2024)
Table 18. Ranking of Global Top Long-Acting Monoclonal Antibodies Companies by Revenue (US$ Million) in 2024
Table 19. Global 5 Largest Players Market Share by Long-Acting Monoclonal Antibodies Revenue (CR5 and HHI) & (2020-2025)
Table 20. Global Key Players of Long-Acting Monoclonal Antibodies, Headquarters and Area Served
Table 21. Global Key Players of Long-Acting Monoclonal Antibodies, Product and Application
Table 22. Global Key Players of Long-Acting Monoclonal Antibodies, Date of Enter into This Industry
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Long-Acting Monoclonal Antibodies Market Size by Type (2020-2025) & (US$ Million)
Table 25. Global Long-Acting Monoclonal Antibodies Revenue Market Share by Type (2020-2025)
Table 26. Global Long-Acting Monoclonal Antibodies Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 27. Global Long-Acting Monoclonal Antibodies Revenue Market Share by Type (2026-2031)
Table 28. Global Long-Acting Monoclonal Antibodies Market Size by Application (2020-2025) & (US$ Million)
Table 29. Global Long-Acting Monoclonal Antibodies Revenue Market Share by Application (2020-2025)
Table 30. Global Long-Acting Monoclonal Antibodies Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 31. Global Long-Acting Monoclonal Antibodies Revenue Market Share by Application (2026-2031)
Table 32. North America Long-Acting Monoclonal Antibodies Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 33. North America Long-Acting Monoclonal Antibodies Market Size by Country (2020-2025) & (US$ Million)
Table 34. North America Long-Acting Monoclonal Antibodies Market Size by Country (2026-2031) & (US$ Million)
Table 35. Europe Long-Acting Monoclonal Antibodies Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 36. Europe Long-Acting Monoclonal Antibodies Market Size by Country (2020-2025) & (US$ Million)
Table 37. Europe Long-Acting Monoclonal Antibodies Market Size by Country (2026-2031) & (US$ Million)
Table 38. Asia-Pacific Long-Acting Monoclonal Antibodies Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 39. Asia-Pacific Long-Acting Monoclonal Antibodies Market Size by Region (2020-2025) & (US$ Million)
Table 40. Asia-Pacific Long-Acting Monoclonal Antibodies Market Size by Region (2026-2031) & (US$ Million)
Table 41. Latin America Long-Acting Monoclonal Antibodies Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 42. Latin America Long-Acting Monoclonal Antibodies Market Size by Country (2020-2025) & (US$ Million)
Table 43. Latin America Long-Acting Monoclonal Antibodies Market Size by Country (2026-2031) & (US$ Million)
Table 44. Middle East & Africa Long-Acting Monoclonal Antibodies Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 45. Middle East & Africa Long-Acting Monoclonal Antibodies Market Size by Country (2020-2025) & (US$ Million)
Table 46. Middle East & Africa Long-Acting Monoclonal Antibodies Market Size by Country (2026-2031) & (US$ Million)
Table 47. Eli Lilly Company Details
Table 48. Eli Lilly Business Overview
Table 49. Eli Lilly Long-Acting Monoclonal Antibodies Product
Table 50. Eli Lilly Revenue in Long-Acting Monoclonal Antibodies Business (2020-2025) & (US$ Million)
Table 51. Eli Lilly Recent Development
Table 52. Abbott Laboratories Company Details
Table 53. Abbott Laboratories Business Overview
Table 54. Abbott Laboratories Long-Acting Monoclonal Antibodies Product
Table 55. Abbott Laboratories Revenue in Long-Acting Monoclonal Antibodies Business (2020-2025) & (US$ Million)
Table 56. Abbott Laboratories Recent Development
Table 57. AstraZeneca Company Details
Table 58. AstraZeneca Business Overview
Table 59. AstraZeneca Long-Acting Monoclonal Antibodies Product
Table 60. AstraZeneca Revenue in Long-Acting Monoclonal Antibodies Business (2020-2025) & (US$ Million)
Table 61. AstraZeneca Recent Development
Table 62. Amgen Company Details
Table 63. Amgen Business Overview
Table 64. Amgen Long-Acting Monoclonal Antibodies Product
Table 65. Amgen Revenue in Long-Acting Monoclonal Antibodies Business (2020-2025) & (US$ Million)
Table 66. Amgen Recent Development
Table 67. Bayer AG Company Details
Table 68. Bayer AG Business Overview
Table 69. Bayer AG Long-Acting Monoclonal Antibodies Product
Table 70. Bayer AG Revenue in Long-Acting Monoclonal Antibodies Business (2020-2025) & (US$ Million)
Table 71. Bayer AG Recent Development
Table 72. Johnson & Johnson Company Details
Table 73. Johnson & Johnson Business Overview
Table 74. Johnson & Johnson Long-Acting Monoclonal Antibodies Product
Table 75. Johnson & Johnson Revenue in Long-Acting Monoclonal Antibodies Business (2020-2025) & (US$ Million)
Table 76. Johnson & Johnson Recent Development
Table 77. Pfizer Company Details
Table 78. Pfizer Business Overview
Table 79. Pfizer Long-Acting Monoclonal Antibodies Product
Table 80. Pfizer Revenue in Long-Acting Monoclonal Antibodies Business (2020-2025) & (US$ Million)
Table 81. Pfizer Recent Development
Table 82. GlaxoSmithKline Company Details
Table 83. GlaxoSmithKline Business Overview
Table 84. GlaxoSmithKline Long-Acting Monoclonal Antibodies Product
Table 85. GlaxoSmithKline Revenue in Long-Acting Monoclonal Antibodies Business (2020-2025) & (US$ Million)
Table 86. GlaxoSmithKline Recent Development
Table 87. Merck Company Details
Table 88. Merck Business Overview
Table 89. Merck Long-Acting Monoclonal Antibodies Product
Table 90. Merck Revenue in Long-Acting Monoclonal Antibodies Business (2020-2025) & (US$ Million)
Table 91. Merck Recent Development
Table 92. Novartis Company Details
Table 93. Novartis Business Overview
Table 94. Novartis Long-Acting Monoclonal Antibodies Product
Table 95. Novartis Revenue in Long-Acting Monoclonal Antibodies Business (2020-2025) & (US$ Million)
Table 96. Novartis Recent Development
Table 97. Research Programs/Design for This Report
Table 98. Key Data Information from Secondary Sources
Table 99. Key Data Information from Primary Sources
Table 100. Authors List of This Report


List of Figures
Figure 1. Long-Acting Monoclonal Antibodies Picture
Figure 2. Global Long-Acting Monoclonal Antibodies Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Long-Acting Monoclonal Antibodies Market Share by Type: 2024 VS 2031
Figure 4. Murine Source Features
Figure 5. Chimeric Source Features
Figure 6. Human Source Features
Figure 7. Global Long-Acting Monoclonal Antibodies Market Size by Application (2020-2031) & (US$ Million)
Figure 8. Global Long-Acting Monoclonal Antibodies Market Share by Application: 2024 VS 2031
Figure 9. Cancer Case Studies
Figure 10. Autoimmune Diseases Case Studies
Figure 11. Inflammatory Diseases Case Studies
Figure 12. Infectious Diseases Case Studies
Figure 13. Others Case Studies
Figure 14. Long-Acting Monoclonal Antibodies Report Years Considered
Figure 15. Global Long-Acting Monoclonal Antibodies Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 16. Global Long-Acting Monoclonal Antibodies Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 17. Global Long-Acting Monoclonal Antibodies Market Share by Region: 2024 VS 2031
Figure 18. Global Long-Acting Monoclonal Antibodies Market Share by Players in 2024
Figure 19. Global Top Long-Acting Monoclonal Antibodies Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Long-Acting Monoclonal Antibodies as of 2024)
Figure 20. The Top 10 and 5 Players Market Share by Long-Acting Monoclonal Antibodies Revenue in 2024
Figure 21. North America Long-Acting Monoclonal Antibodies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. North America Long-Acting Monoclonal Antibodies Market Share by Country (2020-2031)
Figure 23. United States Long-Acting Monoclonal Antibodies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Canada Long-Acting Monoclonal Antibodies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. Europe Long-Acting Monoclonal Antibodies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. Europe Long-Acting Monoclonal Antibodies Market Share by Country (2020-2031)
Figure 27. Germany Long-Acting Monoclonal Antibodies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. France Long-Acting Monoclonal Antibodies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. U.K. Long-Acting Monoclonal Antibodies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Italy Long-Acting Monoclonal Antibodies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Russia Long-Acting Monoclonal Antibodies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Nordic Countries Long-Acting Monoclonal Antibodies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Asia-Pacific Long-Acting Monoclonal Antibodies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Asia-Pacific Long-Acting Monoclonal Antibodies Market Share by Region (2020-2031)
Figure 35. China Long-Acting Monoclonal Antibodies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Japan Long-Acting Monoclonal Antibodies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. South Korea Long-Acting Monoclonal Antibodies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Southeast Asia Long-Acting Monoclonal Antibodies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. India Long-Acting Monoclonal Antibodies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Australia Long-Acting Monoclonal Antibodies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Latin America Long-Acting Monoclonal Antibodies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Latin America Long-Acting Monoclonal Antibodies Market Share by Country (2020-2031)
Figure 43. Mexico Long-Acting Monoclonal Antibodies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Brazil Long-Acting Monoclonal Antibodies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Middle East & Africa Long-Acting Monoclonal Antibodies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Middle East & Africa Long-Acting Monoclonal Antibodies Market Share by Country (2020-2031)
Figure 47. Turkey Long-Acting Monoclonal Antibodies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. Saudi Arabia Long-Acting Monoclonal Antibodies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. UAE Long-Acting Monoclonal Antibodies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 50. Eli Lilly Revenue Growth Rate in Long-Acting Monoclonal Antibodies Business (2020-2025)
Figure 51. Abbott Laboratories Revenue Growth Rate in Long-Acting Monoclonal Antibodies Business (2020-2025)
Figure 52. AstraZeneca Revenue Growth Rate in Long-Acting Monoclonal Antibodies Business (2020-2025)
Figure 53. Amgen Revenue Growth Rate in Long-Acting Monoclonal Antibodies Business (2020-2025)
Figure 54. Bayer AG Revenue Growth Rate in Long-Acting Monoclonal Antibodies Business (2020-2025)
Figure 55. Johnson & Johnson Revenue Growth Rate in Long-Acting Monoclonal Antibodies Business (2020-2025)
Figure 56. Pfizer Revenue Growth Rate in Long-Acting Monoclonal Antibodies Business (2020-2025)
Figure 57. GlaxoSmithKline Revenue Growth Rate in Long-Acting Monoclonal Antibodies Business (2020-2025)
Figure 58. Merck Revenue Growth Rate in Long-Acting Monoclonal Antibodies Business (2020-2025)
Figure 59. Novartis Revenue Growth Rate in Long-Acting Monoclonal Antibodies Business (2020-2025)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed
Choose Your Edition
Add to cart

Our team would be happy to assist you with your queries.

Contact us

About us

Accurate data, The latest market trends, And deeper research directions.

Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals

Latest reports

Useful links

Our Contacts

Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China

(+86) 159 1069 5232

sales@hengceresearch.com
hengceresearch.com

Allow cookies